Abstract: The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.

Abstract: Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.

Abstract: An adjuvant composition for modifying the spray properties of an aqueous pesticide composition contains (a) at least one fatty deposition control agent, and (b)(ii) a liquid medium, one or more hydrotropes, and, optionally one or more surfactants, or (b)(ii) one or more surfactants, and adjuvant compositions for modifying the spray properties of an aqueous pesticide composition contains (c) at least one deposition control agent, and (d)(ii) a liquid medium, one or more hydrotropes, and, optionally one or more surfactants, or (d)(ii) one or more surfactants, and use thereof in agricultural applications.

Abstract: An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

Abstract: The present invention relates to an injectable pharmaceutical formulation comprising a compound of formula (I) the formulation being buffered to a pharmaceutically acceptable pH-value, especially a pH-value of from 2 to 6, in particular a pH value of from 3 to 5.5, preferred a pH-value of about 4 to 5, particularly preferred about 5.

Abstract: An oral care composition having a soluble zinc polyphosphate complex made by combining ingredients including an inorganic zinc salt, and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of treating a subject suffering from dentinal sensitivity applying the oral care composition to the teeth and gums of the subject.

Abstract: This invention relates to oral care compositions comprising a basic amino acid or salt thereof, a zinc source, and a preservative, as well as to methods of using and of making these compositions.

Abstract: The present disclosure provides a glass composition that include from about 50 mol % to about 95 mol % of B2O3; from about 5 mol % to about 50 mol % of one or more glass components selected from the group consisting of: Li2O, Rb2O, K2O, Na2O, SrO, CaO, MgO, and ZnO. The glass composition includes less than 30 mol % of Rb2O. The glass composition is a quaternary system. The glass composition is a particulate material that includes particles that are from about 1 to about 50 ?m in size. The glass composition loses at least 5 mass % within 24 hours when exposed to a buffered saline solution. The glass composition may be used to desensitize dentin. The present disclosure also provides a dentin-desensitizing composition.

Abstract: A soluble zinc polyphosphate complex made by combining ingredients which include an inorganic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of making this soluble zinc polyphosphate.

Abstract: Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Abstract: A skin whitening composition includes ?-mangostin or a cosmetically acceptable salt thereof as an effective ingredient. ?-Mangostin represented by Chemical Formula 1 suppresses the expression of tyrosinase and TRP-1 (tyrosinase-related protein-1) and induces autophagy of a melasosome. As such, it was confirmed that the ?-mangostin not only suppresses melanin production but also exhibits the effect of removing previously formed melanin. Accordingly, the ?-mangostin can be advantageously used as a functional material for skin whitening and skin lightening.

Abstract: Described herein is a method of using as perfuming ingredients, e.g. to impart odor notes of the fruity, fruity-exotic types, cyclopentanone compounds of formula in a form of any one of its stereoisomers or a mixture thereof, and wherein n represents 1 or 2.

Abstract: Embodiments relate to a composition comprising nanohydroxyapatite (NHAP) in an amount about 0.5 wt. % to about 50 wt. % of the composition having a particle size in a range of about 20-100 nm, an abrasive, a sweetener, and a natural oil, wherein the composition does not contain glycerin and fluoride, wherein the composition is alkaline and a dental product, and wherein the natural oil is a plant product.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: Provided is an oral composition containing particles that have properties to seal dentinal tubules and excellent adhesion properties in dentinal tubules. Specifically, provided is an oral composition containing hydroxyapatite particles, wherein the hydroxyapatite particles have a ratio of a diffraction peak intensity around 2?=32° to a diffraction peak intensity around 2?=26° of 0.8 to 1.6 in an x-ray powder diffraction pattern as measured with CuK? characteristic X-rays.

Abstract: The invention relates to delivery systems that allow for the pulsatile release of a substance, such as a drug, in response to a change in pH. More specifically, it relates to drug administration to the GI tract, in particular to site-specific intestinal drug delivery via the oral route. Provided is a pH-controlled pulsatile release system (PPRS) comprising a core surrounded by a coating layer, wherein said core comprises an active substance and wherein said coating layer comprises a pH-sensitive coating material wherein a swellable agent is embedded. Said swellable agent is capable of taking up at least 1.1 times, preferably at least 5 times, more preferably at least 10 times its weight in water. Also provided is a pharmaceutical composition comprising a PPRS, in particular a colon-specific PPRS.